<DOC>
	<DOCNO>NCT02926833</DOCNO>
	<brief_summary>This phase 1-2 , open-label study subject refractory DLBCL , evaluate safety efficacy KTE-C19 , autologous anti-CD19 chimeric antigen receptor ( CAR ) T cell therapy , combination atezolizumab , humanize , monoclonal antibody bind PD-L1 block interaction PD-1 B7.1 receptor . The trial separate two distinct phase designate phase 1 phase 2 .</brief_summary>
	<brief_title>A Study Evaluating KTE-C19 Combination With Atezolizumab Subjects With Refractory Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key 1 . Histologically confirm : Diffuse Large B Cell Lymphoma ( DLBCL ) 2 . Chemotherapyrefractory disease , define one following : Stable disease ( duration stable disease must less equal 6 month ) progressive disease best response recent chemotherapy contain regimen Disease progression recurrence less equal 12 month prior autologous SCT 3 . Subjects must receive adequate prior therapy include minimum : antiCD20 monoclonal antibody unless investigator determines tumor CD20negative anthracycline contain chemotherapy regimen 4 . At least one measurable lesion per revise IWG Response Criteria 5 . Age 18 old 6 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 7 . Adequate organ bone marrow function 8 . All subject legally appoint representatives/caregivers , must personally sign date IRB/IEC approve consent form initiating study specific procedure activity . Key 1 . History malignancy nonmelanoma skin cancer carcinoma situ ( e.g . cervix , bladder , breast ) follicular lymphoma unless disease free least 3 year 2 . History allogeneic stem cell transplantation 3 . Prior CAR therapy genetically modify T cell therapy 4 . Clinically significant active infection 5 . Known history infection HIV hepatitis B ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) 6 . Subjects detectable cerebrospinal fluid malignant cell brain metastasis history cerebrospinal fluid malignant cell brain metastases 7 . History seizure disorder , cerebrovascular ischemia/hemorrhage , dementia , cerebellar disease , autoimmune disease CNS involvement 8 . History autoimmune disease . Patients history autoimmunerelated hypothyroidism stable dose thyroid replacement hormone patient control type 1 diabetes mellitus stable insulin regimen may eligible study . 9 . History idiopathic pulmonary fibrosis , organize pneumonia ( e.g. , bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis per chest CT scan screening . History radiation pneumonitis radiation field ( fibrosis ) allow . 10 . Prior treatment PDL1 inhibitor , PD1 inhibitor , antiCTLA4 , antiCD137 , antiOX40 immune checkpoint blockade activator therapy exception subject receive atezolizumab study eligible retreatment 11 . Prior CD19 target therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>